Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-008088.pdf
0001558370-16-008088.rtf
0001558370-16-008088.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-028516.pdf
0001179110-16-028516.rtf
0001179110-16-028516.xls
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-007713.pdf
0001558370-16-007713.rtf
0001558370-16-007713.xls
10-Q Quarterly report which provides a continuing view of a company's financial position View HTML
0001558370-16-007817.pdf
0001558370-16-007817.rtf
0001558370-16-007817.xls
EX-101.INS - EX-101.INS
CT ORDER CT ORDER
9999999997-16-024629.pdf
EFFECT EFFECT View HTML
9999999995-16-005229.pdf
9999999995-16-005229.rtf
9999999995-16-005229.xls
10-Q/A Amendment to a previously filed 10-Q View HTML
0001558370-16-006732.pdf
0001558370-16-006732.rtf
0001558370-16-006732.xls
S-3/A Pre-effective amendment to an S-3 filing View HTML
0001558370-16-006734.pdf
0001558370-16-006734.rtf
0001558370-16-006734.xls
CORRESP CORRESP View HTML
0001558370-16-006736.pdf
0001558370-16-006736.rtf
0001558370-16-006736.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026949.pdf
0001179110-16-026949.rtf
0001179110-16-026949.xls